Abstract:Background: Randomized studies have shown that the addition of weekly cetuximab to FOLFOX or FOLFIRI improves clinical outcome in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer (mCRC). This Asia-Pacific multicenter non-randomized phase II study investigated the efficacy and safety of both FOLFOX and FOLFIRI in combination with every 2 weeks cetuximab as first-line therapy in patients with KRAS wild-type mCRC. Methods: Eligible patients received every 2 weeks cetuximab (day 1, 500 mg/m2 every 14 days) with, based on investigator's choice, either FOLFOX (oxaliplatin 100 mg/m2, folinic acid [FA] 200 mg/m2 L-form or 400 mg/m2 racemic, then 5-fluorouracil [5-FU], as a 400 mg/m2 iv bolus and a 2400 mg/m2 infusion over 46 h) or FOLFIRI (irinotecan 180 mg/m2, FA 200 mg/m2 L-form, or 400 mg/m2 racemic, then 5-FU, as a 400 mg/m2 iv bolus and a 2400 mg/m2 infusion over 46 h). Study treatment was continued until disease progression, the occurrence of unacceptable toxicity or consent withdrawal. The primary endpoint was tumor response; assessed radiologically (RECIST 1.0) every 8 weeks. Results: Data cut-off was 86 weeks after the date of the last patient included. The intention to treat (ITT)/safety population comprised 289 patients; 65.1% received FOLFOX plus cetuximab and 34.9% FOLFIRI plus cetuximab. Baseline characteristics were generally well balanced between treatment groups. However, leukocyte count >10000/mm3 was more frequent (16.5% vs 7.9%) and prior adjuvant treatment less frequent (21.3% vs 46.5%) in patients receiving FOLFOX plus cetuximab. A best overall response (complete + partial) rate of 58.8% and a median progression-free survival (mPFS) time of 11.1 months were observed in the combined ITT population (Table). 70.9% of patients showed ≥20% reduction in tumor diameter at 8 weeks from baseline. A post-hoc analysis showed a mPFS time of 12.7 months for this group. The overall R0 resection rate in the ITT population was 10.0%. Survival data are not yet mature. Cetuximab dose intensity was >80% in 77.7% of patients in the FOLFOX plus cetuximab group and 74.3% of patients in the FOLFIRI plus cetuximab group. The most frequent grade 3/4 adverse events (reported for >10% of patients in either arm) were neutropenia, diarrhea, hypokalemia, neuropathy (FOLFOX plus cetuximab group only) and skin reactions. Conclusion: In this study population from the Asia-Pacific region, first-line treatment with chemotherapy plus cetuximab was active and well-tolerated. Efficacy and safety profiles of every 2 weeks cetuximab combined with FOLFOX or FOLFIRI were similar to those reported for either chemotherapy plus weekly cetuximab in pivotal studies.Table Open table in a new tab

Cetuximab Combined with FOLFOX4 As the First-Line Treatment for Advanced Gastric Cancer: Report of 25 Cases from a Single Institution

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial

Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial

Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care

Phase Ii Study of Cetuximab in Combination with Modified Folfiri in Patients with Advanced Gastric Cancer Who Failed First-Line Chemotherapy (effi Study)

A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

Anti-PD-1 Antibody HX008 Combined with Oxaliplatin Plus Capecitabine for Advanced Gastric or Esophagogastric Junction Cancer: a Multicenter, Single-Arm, Open-Label, Phase Ib Trial

Envafolimab Plus Chemotherapy in Advanced Gastric or Gastroesophageal Junction (G/GEJ) Cancer.

[Cetuximab in Combination with Chemotherapy for Patients with Gastrointestinal Cancer].

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial

Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer

Efficacy and Safety of Epirubicin,Oxaliplatin and Capecitabine as the First-Line Treatment for Patients with Metastatic Gastric Cancer

First-Line Cetuximab with Folfox or Folfiri Every 2 Weeks in Kras Wild-Type Metastatic Colorectal Cancer: Phase II Apec Study

Phase Ii Study of Epirubicin Plus Oxaliplatin and Infusional 5-Fluorouracil As First-Line Combination Therapy in Patients with Metastatic or Advanced Gastric Cancer

A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) As First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer

A Phase Ii, Open-Label, Multicenter, Prospective Study of Paclitaxel Plus Capecitabine with Subsequent Capecitabine Maintenance Therapy As First-Line Treatment for Metastatic or Recurrent Gastric Cancer

Trastuzumab Plus Docetaxel And Capecitabine As A First-Line Treatment For Her2-Positive Advanced Gastric Or Gastroesophageal Junction Cancer: A Phase Ii, Multicenter, Open-Label, Single-Arm Study

The Multicenter, Phase Ii Prospective Study of Paclitaxel Plus Capecitabine As First-Line Chemotherapy in Advanced Gastric Carcinoma

Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors

Clinical study on cetuximab combined with FOLFOX4 chemotherapy in treatment of metastatic colorectal cancer

Efficacy and Safety of Every-2-weeks Cetuximab Combined with FOLFOX or FOLFIRI As First-Line Therapy in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (mcrc): an Asia-Pacific Nonrandomized Phase II Study (APEC).